Current strategies of anticoagulation therapy for patients with non-valvular atrial fibrillation

by Masahiro Yasaka
Published 2012-12-01

Development of a tool to improve the quality of decision making in atrial fibrillation

by Street Richard L, Fraenkel Liana, Fried Terri R
Published 2011-10-01

Gender-related differences in presentation and treatment of patients with non-valvular atrial fibrillation: results from RAMSES study

by Volkan Doğan, Özcan Başaran, Osman Beton, Mehmet Tekinalp, Ahmet Çağrı Aykan, Ezgi Kalaycıoğlu, İsmail Bolat, Onur Taşar, Özgen Şafak, Macit Kalçık, Cevat Kırma, Murat Biteker
Published 2017-01-01

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation

by Faye L. Norby, Lindsay G.S. Bengtson, Pamela L. Lutsey, Lin Y. Chen, Richard F. MacLehose, Alanna M. Chamberlain, Ian Rapson, Alvaro Alonso
Published 2017-09-01

Prospective Observational Study of Safety of Early Treatment with Edoxaban in Patients with Ischemic Stroke and Atrial Fibrillation (SATES Study)

by Giovanni Frisullo, Paolo Profice, Valerio Brunetti, Irene Scala, Simone Bellavia, Aldobrando Broccolini, Pietro Caliandro, Riccardo Di Iorio, Roberta Morosetti, Fabio Pilato, Renzo Laborante, Giacomo Della Marca
Published 2021-12-01

The relationship between polymorphisms of P-selectin genes and plasma P-selectin concentration with thrombosis in non-valvular atrial fibrillation of Kazakh ethnicity

by Maerjiaen Bakeyi, Muhuyati
Published 2020-08-01

Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study

by Rungroj Krittayaphong, Arjbordin Winijkul, Komsing Methavigul, Wattana Wongtheptien, Chaiyasith Wongvipaporn, Treechada Wisaratapong, Rapeephon Kunjara-Na-Ayudhya, Smonporn Boonyaratvej, Chulalak Komoltri, Pontawee Kaewcomdee, Ahthit Yindeengam, Piyamitr Sritara, for the COOL-AF Investigators
Published 2018-08-01

Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation

by Daiki Shimomura, Yoshihisa Nakagawa, MD, Hirokazu Kondo, MD, Toshihiro Tamura, MD, Masashi Amano, MD, Yukiko Hayama, MD, Naoaki Onishi, MD, Yodo Tamaki, MD, Makoto Miyake, MD, Kazuaki Kaitani, MD, Chisato Izumi, MD, Masahiko Hayashida, Aya Fukuda, Fumihiko Nakamura, MD, Seiji Kawano, MD
Published 2015-08-01

STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION. WHAT ROCKET AF STUDY RESULTS SAY

by I. S. Yavelov
Published 2017-11-01

Use of Novel oral anticoagulants (NOACs) in patients with risk of stroke in non valvular Atrial Fibrillation (AF)

by Fawad Farooq, Muhammad Hashim, Musa Karim, Ali Yasir
Published 2017-12-01

Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation

by Maria Grazia Celeste, Francesca De Marco, Claudio Fresco, Giuseppe Musumeci, Roberto Ravasio
Published 2017-11-01

Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA)

by Monelli M, Molteni M, Cassetti G, Bagnara L, De Grazia V, Zingale L, Zilli F, Bussotti M, Totaro P, De Maria B, Dalla Vecchia LA
Published 2019-02-01

Study design of GENERAL (general practitioners and embolism prevention in NVAF patients treated with rivaroxaban: Real-life evidence): A multicenter prospective cohort study in pri...

by Kengo Kusano, MD, PhD, Masaharu Akao, MD, PhD, Hikari Tsuji, MD, Kunihiko Matsui, MD, MPH, Shinya Hiramitsu, MD, Yutaka Hatori, MD, Hironori Odakura, MD
Published 2017-08-01

Impact of Non-vitamin K Antagonist Oral Anticoagulant Withdrawal on Stroke Outcomes

by Joong Hyun Park, Sang Won Han, Kyung-Yul Lee, Hye-Yeon Choi, Kyeongyeol Cheon, Han-Jin Cho, Yo Han Jung, Hyung Jong Park, Hyo Suk Nam, Ji Hoe Heo, Hye Sun Lee, Gustavo Saposnik, Young Dae Kim
Published 2018-12-01

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

by Shannon L. Reynolds, Sameer R. Ghate, Richard Sheer, Pranav K. Gandhi, Chad Moretz, Cheng Wang, Stephen Sander, Mary E. Costantino, Srinivas Annavarapu, George Andrews
Published 2017-06-01

Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation

by Marco Bellone, Lorenzo Pradelli, Mario Bo
Published 2018-02-01

Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines

by Alesha J. Smith, Natalie J. Medlicott, David M. Reith, Bryan H. Simpson
Published 2020-01-01

Successful Cerebral Hemorrhage Control with Prothrombin Complex Concentrate in a Patient on Edoxaban Therapy: A Case Report

by Galbiati G
Published 2020-01-01

Approaches to anticoagulation therapy selection in patients with non-valvular atrial fibrillation and ischemic heart disease

by N. A. Koziolova, M. V. Surovtseva
Published 2016-04-01

Increased levels of red cell distribution width is correlated with presence of left atrial stasis in patients with non-valvular atrial fibrillation

by Adnan Kaya, Ceyhan Tukkan, Ahmet Taha Alper, Baris Gungor, Kazim Serhan Ozcan, Mustafa Adem Tatlisu, Ahmet Ilker Tekkesin, Fatma Ozpamuk Karadeniz, Gulay Gok, Osman Kayapinar
Published 2017-05-01